This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tangen, C. M Search for Related Content PubMed PubMed Citation Articles by Tangen, C. M Social Bookmarking                         What's this?

Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees

Dennis O Dixon

National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; NIAID/NIH, MSC 7609, Bethesda, MD 20892-7609, USA dd23a{at}nih.giv

Ralph S Freedman

University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Jay Herson

Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

Michael Hughes

Harvard School of Public Health, Boston, MA, USA

KyungMann Kim

University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Michael H Silverman

BioStrategics Consulting, Ltd., Marblehead, MA, USA

Catherine M Tangen

Fred Hutchinson Cancer Research Center, Seattle, WA, USA

This is a commissioned report by a writing committee formed by the Society for Clinical Trials. The committee was formed with the objectives of 1) reviewing data monitoring guidelines for confirmatory (phase III) trials published by the National Institutes of Health, US Food and Drug Administration, Veterans Administration, and the International Conference on Harmonisation and 2) proposing corresponding guidelines for exploratory clinical trials (ie, most phase I and phase II trials and others not requiring a fully independent data monitoring committee). These trials typically involve fewer subjects and are of shorter duration than phase III trials. Nevertheless there are safety concerns, especially because these are often the first human trials for a new intervention. Recommendations are given for appropriate elements of a data monitoring plan, decision criteria for institution of a data monitoring committee (DMC), and critical elements for a DMC to consider in exploratory trials. Review and approval of data monitoring plans are suggested to fall under Institutional Review Board purview. Forming a committee with all the characteristics of a traditional phase III trial monitoring committee may be warranted for a small fraction of exploratory trials. Such a panel could consist of both trial investigators and outside members. The paper concludes with examples of data and safety monitoring practice from the University of Wisconsin Comprehensive Cancer Center and the AIDS Clinical Trials Groups.

Clinical Trials, Vol. 3, No. 3, 314-319 (2006)
DOI: 10.1191/1740774506cn149oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. A Taylor, L. Chaisson, and J. Sugarman Enhancing communication among data monitoring committees and institutional review boards Clinical Trials, June 1, 2008; 5(3): 277 - 282. [Abstract] [PDF]